Use of inmunoconjugado with anti-cd19 Antibody for the treatment of symptoms maitansinoide B cell tumors

摘要

Refers to a method that includes the steps of: (a) manage the patient a dose of 55mg / m2 of the inmunoconjugado maitansinoide anti-cd19, comprising the conjugate HUB4 - DM4; (b) manage the patient 3 subsequent doses of 55mg / m2, separated in time by intervals A Week,The anti-cd19; (c) manage the patient at least 3 subsequent dose of 55 mg / m2 of inmunoconjugado of maitansinoide anti-cd19, separated in time by intervals of two weeks. This method is useful for treating the symptom of bcd19 + tumor cells, including non Hodgkin's Lymphoma.